A plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. 

Report side effects/adverse events at 1-877-825-3327 or www.fda.gov/medwatch.

Dawnzera is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Report side effects/adverse events at 1-800-FDA-1088 or www.fda.gov/medwatch.